anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Syndromic surveillance is an effective tool for enabling the timely detection of infectious disease outbreaks and facilitating the implementation of effective mitigation strategies by public health authorities. While various information sources are currently utilized to collect syndromic signal data for analysis, the aggregated measurement of cough, an important symptom for many illnesses, is not widely employed as a syndromic signal. With recent advancements in ubiquitous sensing technologies, it becomes feasible to continuously measure population-level cough incidence in a contactless, unobtrusive, and automated manner. In this work, we demonstrate the utility of monitoring aggregated cough count as a syndromic indicator to estimate COVID-19 cases. In our study, we deployed a sensor-based platform (Syndromic Logger) in the emergency room of a large hospital. The platform captured syndromic signals from audio, thermal imaging, and radar, while the ground truth data were collected from the hospital's electronic health record. Our analysis revealed a significant correlation between the aggregated cough count and positive COVID-19 cases in the hospital (Pearson correlation of 0.40, p-value < 0.001). Notably, this correlation was higher than that observed with the number of individuals presenting with fever (ρ = 0.22, p = 0.04), a widely used syndromic signal and screening tool for such diseases. Furthermore, we demonstrate how the data obtained from our Syndromic Logger platform could be leveraged to estimate various COVID-19-related statistics using multiple modeling approaches. Aggregated cough counts and other data, such as people density collected from our platform, can be utilized to predict COVID-19 patient visits related metrics in a hospital waiting room, and SHAP and Gini feature importance-based metrics showed cough count as the important feature for these prediction models. Furthermore, we have shown that predictions based on cough counting outperform models based on fever detection (e.g., temperatures over 39°C), which require more intrusive engagement with the population. Our findings highlight that incorporating cough-counting based signals into syndromic surveillance systems can significantly enhance overall resilience against future public health challenges, such as emerging disease outbreaks or pandemics.
Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
BACKGROUND: Tetralogy of Fallot is the most prevalent cyanotic CHD. With the advent of advanced surgical methods, the majority of tetralogy of Fallot patients reach adulthood. However, many need re-intervention for the residual anomalies including residual right ventricular outflow obstruction, pulmonary regurgitation, residual ventricular septal defects, and progressive aortic dilatation. Aortic dilation could lead to aortic regurgitation or dissection requiring surgical correction. In the current study, we aimed to determine the prevalence and outcomes of aortic root dilatation in adults with repaired tetralogy of Fallot in our tertiary care centre.
METHODS: In this retrospective study, 730 consecutive patients with history of repaired tetralogy of Fallot were included. Aortic diameter at the level of annulus, the sinus of Valsalva, sinotubular junction, and the ascending aorta as measured by echocardiography were evaluated. Prevalence of outcomes necessitating re-intervention including aortic regurgitation and dissection were recorded.
RESULTS: The mean size of annulus, sinus of Valsalva, sinotubular-junction, and ascending aorta in the latest available echocardiography of patients were 2.4+/-0.4 cm, 3.3+/-0.5 cm, 2.9+/-0.5cm, and 3.2+/-0.5cm, respectively. Prevalence of dilatation of sinus of Valsalva, dilation of Ascending aorta, sinotubular-junction, and aortic annulus was 28.7%, 21%, 8.3%, and 1 %, respectively. Five patients had severe aortic regurgitation (0.6%) and underwent surgical repair. One of these patients presented with acute aortic dissection.
CONCLUSION: Aortic dilation is common in tetralogy of Fallot but prevalence of redo surgery for aortic dilation, regurgitation, and adverse events including acute dissection is low.
Systems and methods for improving the degree to which programs utilize processor resources during execution. A number of different versions of a program are received, as is a set of performance metrics describing desired performance of the program versions. The programs are then analyzed to determine the amount of processor resources used on a particular processor when the programs are executed to meet the performance metrics. At runtime, a program version that meets its performance metrics without exceeding the available processor resources is selected for execution by the processor. Program versions may be versions written to utilize processors in differing manner, such as by adjusting the numerical precision at which operations are performed or stored. If no program version meets its performance metrics without exceeding the available processor resources, the performance metrics may be reduced and program selection may be based on these reduced performance metrics.
Patients affected by heart failure and diabetes mellitus. These patients previous received an internal cardioverter defibrillator (ICD), and then a catheter ablation for ventricular arrhythmias (VA) therapy. After CA these patients received SLGT2 therapy.
If severe adverse reactions or laboratory abnormalities develop during ribavirin combination therapy, modify or discontinue the dose until the adverse reaction abates or decreases in severity (see Table 4) [see Warnings and Precautions (5)]. If intolerance persists after dose adjustment, combination therapy should be discontinued. Refer to PegIntron labeling for additional information regarding dose reduction of PegIntron.

Dose reduction in pediatric patients is accomplished by modifying the recommended ribavirin dose from the original starting dose of 15 mg/kg daily in a two-step process to 12 mg/kg/day, then to 8 mg/kg/day, if needed (see Table 4).

Ribavirin is contraindicated in patients with creatinine clearance less than 50 mL/min [see Contraindications (4)]. Patients with impaired renal function and those over the age of 50 should be carefully monitored with respect to development of anemia [see Warnings and Precautions (5.2), Use in Specific Populations (8.5), and Clinical Pharmacology (12.3)].

Ribavirin should be administered with caution to patients with pre-existing cardiac disease. Assess cardiovascular status before initiation of treatment and during therapy. If there is any deterioration of cardiovascular status, discontinue combination therapy [see Warnings and Precautions (5.2)].

In patients with a history of stable cardiovascular disease, a permanent dose reduction is required if the hemoglobin decreases by 2 g/dL or more during any 4-week period. If the hemoglobin level remains below 12 g/dL after 4 weeks on a reduced dose, discontinue combination therapy.

Modify or discontinue ribavirin dosing in any patient whose hemoglobin level falls below 10 g/dL (see Table 4) [see Warnings and Precautions (5.2)].

Refer to labeling for INTRON A or PegIntron for additional information about how to reduce an INTRON A or PegIntron dose.
1393155 Administering medicaments ORTHO PHARMACEUTICAL CORP 15 May 1972 [17 May 1971] 22744/72 Heading A5R A device for delivering a medicament 2 to a body cavity comprises a member 1 which when inserted into the body cavity absorbs body fluid and expands, compressing a medicament containing tube 2 located within, around or on the member to dispense the medicament into the body cavity. The member may be formed from a polymeric substance e.g. cellulosic fibres or polymeric materials which itself expands when in contact with body fluids or from an expandible substance which contains a substance which expands when in contact with such fluids. The medicament containing zone may be a hollow in a cylindrical or prismatic member and the medicament may be contained in a collapsible tube 4 of aluminium or ptfe. The tube may be oval in cross-section and may have at least one internal rib or be formed of rectangular cross section to prevent complete flattening. The member may have an outer skin of flexible water permeable material having a high modulus of elasticity. A withdrawal thread 7 may be fitted. In a modification (Fig. 10 not shown) the tube (104) containing the medicament (103) is surrounded by rods (101) made from the stalk of laminaria seaweed which absorbs body fluid and expands. The tube 2 may be around the outside of the member 1, Figure 12 (not shown) or be located on the outer surface of the member 1, Figures 13 and 14 (not shown).
Physical pain leads to a narrow, egocentric focus on the self, in the here and now, particularly when experienced at high intensity levels. When long-term pain is experienced, this narrow focus could be debilitating, since attention to the pain itself may increase its perceived intensity and it could increase negative emotional processes that further contribute to pain-related suffering. One way of overcoming this could be by adopting a more distant view of oneself and the pain, thereby making the pain more abstract. An established way of creating distance is by reflecting on the self, using one's own name and second or third-person singular pronouns, so called third-person self-talk. Earlier research has reported that a psychologically distant perspective could reduce emotional distress when reflecting on negative experiences, reduce feelings of anger after provocation and lead to lower blood pressure. Self-distancing should thus help people mentally reconstrue their pain experience and possibly make the pain signals less cognitively salient.

In the first part of this study, which will be the first registered on ClinicalTrials.gov, we will experimentally induce pain in healthy participants (N = 292) with a cold pressor apparatus. The cold pressor apparatus holds a constant water temperature of 1 degree Celsius, which creates pain in the immersed hand. At the experimental test session, the participant will first be comfortably seated and receive information about the task and the experimental pain induction. They will be instructed to withhold their hand in the cold water for as long as possible, but when they feel that the pain becomes too intense they can choose to remove their hand. After that, a blood pressure measurement will be conducted. Directly after that, the participant will be instructed to put their hand in the cold water-bath (the cold pressor apparatus), and when they put their hand in the cold water a new blood pressure measurement will be conducted. A timer will be started to measure the time in seconds that the participant is able to keep their hand in the cold water. While their hand is in the cold water-bath, the participant will conduct one of the four different interventions (self-distanced, third-person self-talk following a cue-card; self-immersed, first-person self-talk following a cue-card; distraction intervention following a cue-card; no intervention (control)). When the participant removes their hand from the cold water-bath, the time in seconds will be noted and they will immediately be asked to estimate their pain on a Numerical Rating Scale. A short debriefing will conclude the session.
The invention discloses a cnidium fruit extract mediated synthesis nano silver material, a preparation method and application thereof. The nano silver material is in a spherical core-shell structure, the inside of the nano silver material is gathered silver ions, and the outside of the nano silver material is covered cnidium fruit extract. The invention synthesizes the cnidium fruit extract and the silver nitrate to obtain the nano silver material, the average grain diameter is 44.6nm, and the nano silver material is used for trichophyton rubrumThe trichophyton mentagrophytes and candida albicans have good antifungal activity, and the Minimum Inhibitory Concentration (MIC)  90  ) 3.125. Mu.g/mL, 3.125. Mu.g/mL and 0.78125. Mu.g/mL, respectively. The common tinea is treated by using the traditional Chinese medicine fructus cnidii extract to synthesize nano silver, the synthesis method is simple, the particle size is small, the stability is good, and the dispersion is high. The preparation method is green and environment-friendly, and can be widely popularized as the preparation of the efficient antifungal material.
Despite improvements over the past decade, routine mammography screening rates among African American women remain suboptimal. This is especially troubling in light of the fact that African American women have higher breast cancer mortality rates than White and Hispanic women. Multiple studies have revealed that women experience varying levels of pain during mammography, however, African American women report higher levels of mammography-related pain than their White counterparts. In fact, the fear of pain associated with mammography is so prominent that it prevents some women from undergoing routine screenings or follow-ups. Since pain is a major barrier for many African American women in the screening process, studies to assess methods to reduce mammography-related pain are imperative. An FDA-approved radiolucent breast plate cushion has been developed for use during mammography to increase comfort during the exam. The purpose of this study is to evaluate whether use of this radiolucent cushion will decrease the level of pain experienced by African American women undergoing routine screening mammography, positively impact routine mammography screening intentions, and result in greater mammography satisfaction among African American women. 304 women scheduled for mammograms at three community metropolitan mammography facilities participated in this study. One-half of the women were randomized to an Enhanced Mammography (EM) condition in which a radiolucent cushion was used during mammograms. The other half were randomized to a Routine Mammography (RM) condition during which typical exam protocol is followed and no radiolucent cushion was used. Pre- and post-exam surveys assessed anticipated and experienced exam-related pain and discomfort, intentions to return for a future routine mammogram, and general visit satisfaction. A follow-up telephone interview will be conducted with study participants to determine whether they received a follow-up routine screening mammogram 12 to 18 months after they were enrolled in the study (at the time of their last routine screening mammogram) and where they received their mammogram (e.g. did they return to the same facility). If they did not obtain an on-time routine screening mammogram barriers were assessed. The RM and EM groups will be compared for differences.
FIELD: medicine, ophthalmology. SUBSTANCE: the present innovation deals with treating both acute and chronic forms of ocular ischemic diseases. One should apply complex therapy including spasmolytics, anticoagulants and fibrinolytics, antioxidants and antiedemic preparations. Additionally, it is necessary to inject nimotope and actovegin. Moreover, at acute form of the disease nimotope is injected intravenously by drops at the quantity of 50 ml, containing 10 g nimodipin, once daily, every day, for 3-5 d, as for actovegin it should be intravenously injected by drops at the quantity of 500 mg/200 ml physiological solution twice daily, for 8-10 d. In case of chronic form - nimotope is prescribed to be taken inside per 30 mg thrice daily for 18-20 d, and actovegin is introduced by drops intravenously at the quantity of 500 mg/200 ml physiological solution once daily, for 8-10 d. EFFECT: higher efficiency of therapy. 2 cl, 2 ex
Hypotension, during the first 3 hours of infusion, occurred in 12% of all patients and 3% of all courses administered. Bradycardia, during the first 3 hours of infusion, occurred in 3% of all patients and 1% of all courses. In the Phase 3 second-line ovarian study, neither dose nor schedule had an effect on the frequency of hypotension and bradycardia. These vital sign changes most often caused no symptoms and required neither specific therapy nor treatment discontinuation. The frequency of hypotension and bradycardia were not influenced by prior anthracycline therapy.

Significant cardiovascular events possibly related to single-agent paclitaxel occurred in approximately 1% of all patients. These events included syncope, rhythm abnormalities, hypertension and venous thrombosis. One of the patients with syncope treated with paclitaxel at 175 mg/m 2over 24 hours had progressive hypotension and died. The arrhythmias included asymptomatic ventricular tachycardia, bigeminy and complete AV block requiring pacemaker placement. Among patients with NSCLC treated with paclitaxel in combination with cisplatin in the Phase 3 study, significant cardiovascular events occurred in 12% to 13%. This apparent increase in cardiovascular events is possibly due to an increase in cardiovascular risk factors in patients with lung cancer. 

Electrocardiogram (ECG) abnormalities were common among patients at baseline. ECG abnormalities on study did not usually result in symptoms, were not dose-limiting, and required no intervention. ECG abnormalities were noted in 23% of all patients. Among patients with a normal ECG prior to study entry, 14% of all patients developed an abnormal tracing while on study. The most frequently reported ECG modifications were non-specific repolarization abnormalities, sinus bradycardia, sinus tachycardia, and premature beats. Among patients with normal ECGs at baseline, prior therapy with anthracyclines did not influence the frequency of ECG abnormalities.

Cases of myocardial infarction have been reported. Congestive heart failure, including cardiac dysfunction and reduction of left ventricular ejection fraction or ventricular failure, has been reported typically in patients who have received other chemotherapy, notably anthracyclines (see PRECAUTIONS, Drug Interactionssection). 

Atrial fibrillation and supraventricular tachycardia have been reported.
Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using the investigational Et Control option intervention. For Subjects under the Et Control option, the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the well being of the subject.
Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.
OBJECTIVE: To determine the prophylactic effect of hydrocolloid dressings on hypertrophic scarring in post-cesarean section wounds.
METHODS: Patients who underwent cesarean section (C/S) at the authors' hospital and provided informed consent to participate were randomly assigned to the intervention and control groups. The intervention group commenced applying hydrocolloid dressings to the wound on postoperative day 7 or 8 and continued with weekly dressing changes for 6 months. The control group refrained from any dressing application but was followed up. In each group, the condition of the wound was evaluated 6 and 12 months postoperatively using the Japan Scar Workshop Scar Scale 2015, the Patient and Observer Scar Assessment Scale version 2.0, the modified Vancouver Scar Scale, and patient-reported outcomes.
RESULTS: During this period, 135 patients underwent C/S at the authors' institution, and 47 (23 in the intervention group and 24 in the control group) were included in the analysis. In all assessment methods, the intervention group scored lower than the control group at 6 and 12 months after C/S. Twelve months after C/S, hypertrophic scarring (Japan Scar Workshop Scar Scale 2015 score of 6-15) was found in 14 of the 47 (29.8%) patients: 11 of 24 (45.8%) in the control group and 3 of 23 (13.0%) in the intervention group. The intervention's relative risk was 0.623 (95% CI, 0.417-0.930). The risk factor for hypertrophic scarring was midline vertical incision, with an odds ratio of 20.53 (95% CI, 4.18-100.92).
CONCLUSIONS: The study reveals that the application of hydrocolloid dressings to wounds reduces the risk of hypertrophic scarring after C/S.
Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
Take deferasirox oral granules on an empty stomach or with a light meal (contains less than 7% fat content and approximately 250 calories). Examples of light meals include 1 whole wheat English muffin, 1 packet jelly (0.5 ounces), and skim milk (8 fluid ounces) or a turkey sandwich (2 oz. turkey on whole wheat bread w/ lettuce, tomato, and 1 packet mustard) [see Clinical Pharmacology (12.3)]. Administer deferasirox oral granules by sprinkling the full dose on soft food (e.g., yogurt or applesauce) immediately prior to use and administered orally. Deferasirox oral granules should be taken once a day, preferably at the same time each day. Do not take deferasirox oral granules with aluminum-containing antacid products [see Drug Interactions (7.1)].  
For patients who are currently on chelation therapy with deferasirox tablets for oral suspension and converting to deferasirox oral granules, the dose should be about 30% lower, rounded to the nearest whole sachet content for granules. The table below provides additional information on dosing conversion to deferasirox granules.
The clinical validation study of the AI-POD instruments (risk score, CDSS, Citizen App) is designed as a prospective, multicentre observational study. Obese patients (BMI \>30 kg/m2) with suspected CVD who are scheduled for a cardiac CT scan (consisting of calcium scoring and coronary CT angiography) will be included in the study. This clinically indicated cardiac CT scan will serve as a baseline examination, and a second cardiac CT scan will be performed after a follow-up period of 2 years. Both cardiac CT examinations will be performed on a photon-counting CT system (PCCT). In addition to the CT data, clinical data (anthropometry and physical parameters such as body weight, height, age, gender, BMI, waist circumference, waist-to-hip ratio, body impedance analysis, cardiovascular risk factors, medication, previous interventions and operations) will be collected, symptoms and results of echocardiography to determine left ventricular function) as well as laboratory data on (subclinical) inflammation (hsCRP, leukocytes, monocyte activation), lipid disorders (HDL, LDL, total cholesterol, triacylglycerides), glucose homeostasis (HbA1c, fasting glucose, HOMA index), liver and kidney function (creatinine, GFR, GOT/ALAT, GPT/ASAT) are collected at a total of 5 visits over 2 years. Half of all included patients will also be randomised to receive access to the Citizen app and a separate fitness tracker device to record the following data: Activity data such as step count, heart rate, height, weight, gender, age, waist circumference circumference, nutritional data such as calorie intake, nicotine, alcohol, sleep.
Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.